MACE risk findings from major clinical trials help physicians and patients navigate testosterone therapy safety, regulatory guidelines, and essential biomarker monitoring routines.
You sit in a doctor's office reviewing your lab results. Your total testosterone is low, and you have experienced fatigue, low libido, and reduced recovery for months. As you discuss treatment options, a major question arises. You have heard that testosterone replacement therapy might damage your heart, but you have also read that normal hormone levels protect cardiovascular health.
Cardiovascular safety is one of the most debated topics in male hormonal medicine. For decades, researchers, regulatory agencies, and clinicians have examined whether restoring testosterone to physiological ranges increases or decreases the risk of heart attacks, strokes, and related vascular events. The conversation has often swung between alarmist warnings and uncritical enthusiasm.
A rigorous look at modern clinical trials and regulatory guidance reveals a more balanced reality. The scientific record does not support extreme claims on either side. Testosterone replacement therapy neither causes widespread heart attacks when properly prescribed nor acts as a universal shield against cardiovascular disease.
Understanding what the clinical evidence can and cannot tell us requires examining study designs, patient populations, dosing methods, and individual health factors. Evaluating your personal cardiovascular risk before and during therapy allows for safer, better informed decisions.
This article is for educational and informational purposes only. It is not personal medical advice, a clinical diagnosis, or a treatment recommendation. Testosterone replacement therapy involves complex hormonal and cardiovascular considerations that require individual evaluation by a qualified medical professional. Always consult a licensed healthcare provider regarding your symptoms, laboratory tests, existing cardiovascular conditions, and treatment choices.
The relationship between testosterone therapy and cardiovascular health is nuanced. The following points summarize the current clinical consensus and recent trial evidence:
Cardiovascular safety discussions must begin with clear definitions. Testosterone replacement therapy refers to the medical practice of restoring hormone levels to a normal physiological range in men with diagnosed hypogonadism. It is fundamentally different from the illicit use of anabolic steroids or unsupervised protocols that push hormone levels far above normal limits.
A valid clinical diagnosis requires both persistent symptoms and objective laboratory confirmation. Symptoms often include diminished sexual desire, erectile dysfunction, decreased muscle mass, persistent fatigue, and mood changes. However, these symptoms are non-specific and overlap heavily with obesity, sleep apnea, metabolic syndrome, and normal aging.
Laboratory confirmation requires at least two separate fasting morning blood tests. Testosterone secretion follows a circadian rhythm, peaking in the early morning hours. A single low reading is insufficient for a diagnosis because illness, acute stress, poor sleep, and nutritional state can cause transient drops. When evaluating symptoms and lab work, clinicians review the full scope of low testosterone signs and causes to identify underlying health problems before considering therapy.
Cardiovascular risk is not a fixed, universal number. It varies based on age, smoking status, lipid profiles, blood pressure, diabetes, and existing vascular disease. A clinical trial finding from an older population with preexisting heart disease cannot be assumed to apply identically to a young man with no cardiovascular risk factors.
Diagnostic boundaries also separate primary or secondary hypogonadism from age-related hormonal decline. Regulatory agencies continue to maintain limitations of use regarding age-related drops in testosterone without an identifiable organic cause. Evaluating cardiovascular safety requires knowing exactly who is being treated and why.
For many years, the medical community faced conflicting data regarding testosterone therapy and heart health. Some observational studies suggested higher cardiovascular event rates, while others suggested that untreated low testosterone carried greater mortality risk. To resolve this question, regulatory agencies mandated a large-scale, prospective randomized controlled trial.
The TRAVERSE study enrolled 5,246 men aged 45 to 80 across hundreds of clinical sites. To qualify, participants had to show symptoms of hypogonadism, have two fasting morning total testosterone measurements below 300 ng/dL, and have established cardiovascular disease or multiple high-risk cardiovascular factors.
Participants were randomly assigned to receive either a daily 1.62% transdermal testosterone gel or a matching placebo gel. Clinicians adjusted the doses over time to keep testosterone levels within a target range of 350 to 750 ng/dL.
The primary endpoint of the study was the first occurrence of a major adverse cardiovascular event, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial used a noninferiority design to determine whether testosterone therapy was acceptably no worse than placebo by a predefined statistical margin.
The primary outcome occurred in 182 men in the testosterone group, representing 7.0% of participants. In the placebo group, 190 men experienced a primary outcome event, representing 7.3% of participants. The hazard ratio was 0.96 with a 95% confidence interval of 0.78 to 1.17.
These results met the prespecified noninferiority criterion. The secondary composite endpoint, which added coronary revascularization procedures to the primary events, also showed similar event rates between the two groups.
Mean treatment duration in the trial was 21.7 months, while mean patient follow-up was 33 months. This distinction is critical for interpreting the data. While the trial provides robust evidence over a multi-year period, it does not represent decades of continuous exposure.
Alongside the neutral MACE results, the investigators recorded several secondary safety signals. Men in the testosterone group experienced higher reported rates of atrial fibrillation, pulmonary embolism, and acute kidney injury. These findings demonstrate why cardiovascular health cannot be reduced to a single endpoint.
Understanding clinical evidence requires understanding how noninferiority trials work. In a standard superiority trial, researchers seek to prove that a new treatment is better than an existing therapy or a placebo. In a noninferiority trial like TRAVERSE, the goal is to confirm that a treatment does not increase risk beyond a predetermined, acceptable boundary.
The noninferiority margin in TRAVERSE was set at an upper hazard ratio limit of 1.5. Because the actual upper confidence interval reached 1.17, the trial successfully demonstrated noninferiority for its primary MACE composite.
However, noninferiority is not mathematical proof of identical risk. It means that, under the specific conditions tested, testosterone gel did not produce an unacceptable increase in heart attacks, strokes, or cardiovascular deaths. It does not mean the hazard ratio is guaranteed to be 1.0 under all circumstances.
Similarly, a noninferiority result does not prove cardiovascular protection. Some advocates have misinterpreted the slightly lower percentage of events in the testosterone arm as evidence of a protective effect. Because the confidence interval crosses 1.0, the study showed neutral outcomes rather than a statistically significant risk reduction.
Noninferiority trials are also strictly limited to their predefined endpoints. Meeting the noninferiority standard for heart attacks and strokes does not clear a medication of all cardiovascular or systemic risks. The presence of secondary signals such as arrhythmia and venous thromboembolism highlights the need to look at the entire clinical picture.
When researching hormonal health, patients often encounter conflicting claims from different types of studies. Differentiating between randomized controlled trials and observational data is essential for assessing evidence quality.
Randomized controlled trials represent the highest standard for establishing cause and effect. By randomly assigning participants to treatment or placebo groups, researchers balance known and unknown confounding variables between the cohorts. Double-blind designs prevent patient expectations and clinician perceptions from biasing the results.
Observational studies, by contrast, look at health outcomes in real-world databases without assigning treatments. While observational research can examine thousands of patients over extended periods, it is inherently vulnerable to confounding factors.
In observational testosterone studies, two major biases often distort results:
Some observational publications have reported hazard ratios suggesting reduced cardiovascular risk among men on therapy. For example, some datasets cited in professional reviews showed lower heart attack associations with hazard ratios around 0.84. However, these figures cannot be directly compared to randomized trial results because statistical adjustments cannot eliminate all unmeasured baseline differences.
Study quality also depends on treatment adherence and exposure duration. In clinical trials, medication use is tracked, and dosages are systematically adjusted. In observational registries, prescriptions may be filled inconsistently, laboratory targets are rarely uniform, and discontinuation rates are high.
Reviewing published literature on TRT and emerging research requires checking whether a study measured clinical outcomes prospectively or merely analyzed billing records retrospectively.
Regulatory agencies and professional medical societies regularly review clinical evidence to establish safety standards and prescribing parameters. Their statements provide practical guardrails for clinicians and patients.
In February 2025, the United States Food and Drug Administration updated class-wide labeling requirements for prescription testosterone products. After evaluating the TRAVERSE findings and comprehensive clinical data, the agency removed boxed warning language that previously warned of increased major adverse cardiovascular risks.
At the same time, the FDA retained its clear limitation of use regarding age-related hypogonadism. The agency also mandated updated warnings regarding potential increases in blood pressure based on ambulatory blood pressure monitoring studies across various formulations.
Major professional medical associations have published detailed clinical guidelines for managing testosterone deficiency:
These guideline recommendations emphasize caution in unstable cardiac situations. Having stable, long-standing cardiovascular disease does not automatically prevent a man from receiving therapy, but an acute or recent cardiac event requires stabilization before hormone therapy is introduced.
Managing cardiovascular safety during testosterone therapy requires consistent laboratory and physiological monitoring. Biomarkers offer objective insight into how the body responds to treatment over time. Understanding your numbers in context is a core component of testing and biomarkers education.
Total testosterone measures all circulating hormone in the bloodstream, including hormone bound to sex hormone-binding globulin and albumin. Free testosterone represents the unbound fraction that is readily available to tissues.
In clinical trials like TRAVERSE, clinicians adjusted medication doses to achieve total testosterone levels between 350 and 750 ng/dL. This range reflects standard physiological levels for healthy adult men. Pushing levels beyond the upper reference limit increases the likelihood of side effects without providing additional clinical benefits.
Testosterone stimulates erythropoiesis, the biological process by which the bone marrow produces red blood cells. As red blood cell production increases, hematocrit, which is the percentage of whole blood made up of red blood cells, rises accordingly.
Elevated hematocrit increases blood viscosity, making blood thicker and potentially raising the resistance against which the heart must pump. Clinical consensus guidelines recommend monitoring hematocrit at baseline, at three to six months after starting treatment, and annually thereafter.
Most clinical guidelines, including reviews published by the Cleveland Clinic Journal of Medicine, advise keeping hematocrit below 54%. If hematocrit reaches or exceeds 54%, clinicians typically evaluate the patient for underlying causes, adjust the testosterone dosage, switch formulations, or pause therapy until levels normalize.
Blood pressure is a major modifiable risk factor for cardiovascular disease. Testosterone can influence fluid balance, vascular tone, and renal sodium handling. Clinical trials incorporating ambulatory blood pressure monitoring have shown modest average increases in systolic blood pressure in some treated men.
Even small, sustained increases in blood pressure can influence long-term vascular risk. Patients starting testosterone therapy should have their blood pressure checked at every clinical visit and monitor their readings at home. If blood pressure rises significantly, standard antihypertensive management or dosage adjustments are necessary.
Cardiovascular risk is tied to overall metabolic health. Routine monitoring typically includes a fasting lipid panel to evaluate total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides.
Testosterone therapy can cause minor shifts in lipid fractions, such as slight reductions in high-density lipoprotein. However, it may also improve insulin sensitivity and body composition in men with metabolic syndrome. Evaluating these markers together provides a complete picture of cardiovascular health.
To understand how clinical evidence applies in practice, consider the following illustrative clinical models. These scenarios demonstrate how patient history, timing, and laboratory values shape medical decision-making.
A 58-year-old man presents with persistent low libido, fatigue, and two confirmed fasting morning testosterone readings of 220 ng/dL and 240 ng/dL. He has a history of a coronary stent placed four years ago, but his condition is stable, his blood pressure is controlled, and he exercises regularly.
This patient closely resembles the population studied in the TRAVERSE trial. The randomized trial data provide reassuring evidence that restoring his testosterone to a normal range does not increase his risk of major adverse cardiovascular events compared to placebo.
His physician discusses the trial findings, explains the minor risks of secondary events such as arrhythmia, and orders baseline blood tests. They agree on a transdermal gel protocol targeting a mid-normal testosterone level, with scheduled follow-ups to monitor his blood pressure, hematocrit, and cardiac stability.
A 62-year-old man had a myocardial infarction eight weeks ago. During a routine checkup, he mentions experiencing severe fatigue and asks whether testosterone therapy could help his energy levels, noting a previous low lab result.
In this situation, trial findings in stable patients do not override clinical safety guidelines. Professional recommendations from the Endocrine Society and the American Urological Association advise delaying testosterone therapy for three to six months following an acute cardiovascular event.
His physician explains that the cardiovascular system requires time to stabilize following an infarction. They defer hormone therapy, focus on cardiac rehabilitation and secondary prevention medications, and plan to reevaluate his hormonal symptoms and lab values once he passes the recommended waiting window.
A 49-year-old man starts testosterone replacement therapy after showing low testosterone levels and clinical hypogonadism. At his three-month follow-up, his energy has improved, but his clinic blood pressure has risen from a baseline of 124/80 mmHg to 142/90 mmHg.
Although the patient feels better and his major cardiovascular risk remains low, the blood pressure increase is a meaningful clinical finding. The physician reviews home blood pressure logs, confirms the elevation, and initiates a conversation about lifestyle modifications and medical management.
Rather than ignoring the change, the clinician evaluates whether adjusting the testosterone dose or starting a mild antihypertensive medication is appropriate, ensuring that one risk factor is not exchanged for another.
A 54-year-old man receiving intramuscular testosterone injections presents for his six-month lab review. His total testosterone is 680 ng/dL, but his hematocrit has climbed to 55%, crossing the standard 54% clinical threshold.
The physician reviews the result to prevent complications related to blood hyperviscosity. They assess the patient for dehydration, smoking, and sleep apnea, all of which can exacerbate erythrocytosis.
The clinician decides to reduce the injection dose and shortens the follow-up interval to three months to ensure the hematocrit drops back into the safe reference range.
A 32-year-old man with no cardiovascular disease history requests testosterone therapy. He has no significant symptoms of hypogonadism, but a single afternoon blood test showed a total testosterone level of 310 ng/dL, which he believes is suboptimal for physical fitness.
The TRAVERSE evidence does not apply to this individual. The trial exclusively evaluated middle-aged and older men with confirmed symptomatic hypogonadism and elevated baseline cardiovascular risk. Furthermore, FDA labeling clearly restricts approval to medically confirmed hypogonadism rather than lifestyle enhancement.
His doctor explains that his single afternoon reading was taken when hormone levels are naturally lower. They order a proper fasting morning panel, discuss sleep and training factors, and explain that unnecessary hormone therapy carries real risks, including suppression of natural fertility and red blood cell increases, without documented medical benefits. Learning the fundamentals of testosterone and hormonal function helps men understand why afternoon testing often misleads patients.
Public discussions surrounding testosterone and cardiovascular disease frequently feature exaggerated claims. Separating fact from assumption helps clarify what the evidence actually supports.
This belief originated partly from early, flawed observational studies and small trials that reported increased cardiovascular events in specific cohorts. However, the completion of large, well-designed randomized controlled trials has disproven the idea that physiological testosterone replacement therapy causes heart attacks in men with hypogonadism. When prescribed within clinical guidelines and properly monitored, therapy does not increase MACE rates.
At the opposite extreme is the claim that testosterone therapy acts as a preventative treatment against cardiovascular disease. Proponents often point to observational studies showing that men with higher natural testosterone levels have lower rates of cardiovascular illness.
However, natural associations do not prove that administering exogenous hormone creates the same protective effect. In the TRAVERSE study, event rates between the testosterone and placebo groups were statistically equivalent, showing noninferiority rather than cardiovascular protection.
A study demonstrating that a treatment does not increase heart attacks or strokes does not mean the therapy is entirely free of vascular effects. As observed in randomized data, testosterone therapy can raise red blood cell production, increase blood pressure in susceptible individuals, and correlate with higher rates of atrial fibrillation and pulmonary embolism. Cardiovascular safety involves more than just a single composite endpoint.
Much of the highest quality randomized evidence comes from studies utilizing transdermal gels adjusted to maintain mid-normal serum concentrations. These results cannot be blindly applied to long-acting injections, high-dose pellet implants, or regimens that produce wide swings between peak and trough levels. Injectable formulations, for example, tend to produce higher rates of erythrocytosis than daily transdermal gels.
Some patients believe that having high blood pressure, diabetes, or a previous stent completely disqualifies them from hormone therapy. In reality, the TRAVERSE trial specifically enrolled men with established cardiovascular disease or elevated risk profiles. As long as the cardiovascular condition is stable and proper monitoring is maintained, preexisting disease is not an absolute barrier to medically necessary therapy.
A productive consultation regarding testosterone therapy and cardiovascular health should be collaborative and evidence-based. Bringing structured questions to your appointment ensures all relevant risk factors are addressed:
Engaging in this dialogue helps ensure that hormone replacement therapy, if initiated, is integrated into a broader strategy for long-term health and cardiovascular risk reduction.
Revisit this resource whenever you prepare for an annual cardiovascular checkup, receive new hormone or blood test results, or experience changes in your cardiovascular health such as blood pressure shifts or new medications.
Maintaining cardiovascular health while managing testosterone replacement therapy requires separating evidence from assumption, adhering to diagnostic criteria, and prioritizing ongoing clinical monitoring.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
